Federal grants to Kephera Diagnostics LLC
Kephera Diagnostics LLC in Framingham, Massachusetts received $15.5 million in federal grants from fiscal 2021 to 2025, across 11 awards. Its largest program was Allergy and Infectious Diseases Research, with $14.2 million. In fiscal 2025 it was awarded $4.9 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$15.5 million
- Awards11
- Awarded in FY 2025$4.9 million
- Largest award$3.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 2 | $1.3 million |
| FY 2022 | 1 | -$8 |
| FY 2023 | 5 | $4.4 million |
| FY 2024 | 7 | $5.0 million |
| FY 2025 | 7 | $4.9 million |
Programs that fund Kephera Diagnostics LLC
| Program | Awards | Amount |
|---|---|---|
| Allergy and Infectious Diseases Research | 8 | $14.2 million |
| Trans-NIH Research Support | 1 | $508,178 |
| Cardiovascular Diseases Research | 1 | $470,013 |
| Centers for Disease Control and Prevention Investigations and Technical Assistance | 1 | $303,250 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 11 | $15.5 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Point-of-care diagnostic test for t. Cruzi (CHAGAS) infection - project summary chagas disease, caused by infection with the parasite trypanosoma cruzi, is the most prevalent parasitic disease in the western hemisphere, infecting 8-11 million individuals and with over 70 million at risk. The infecti | Allergy and Infectious Diseases Research | March 30, 2023 | $3.0 million |
| Rapid point-of-care assay for diagnosis of neurocysticercosis in seizure patients - project summary epilepsy, a disorder of the brain manifested by seizures, is the fourth most prevalent neurological disease, affecting over 50 million people worldwide, or about 1 out of 150 individuals on average. T | Allergy and Infectious Diseases Research | May 12, 2023 | $3.0 million |
| Biomarker-based test of cure for chagas disease - project summary chagas disease, caused by infection with trypanosoma cruzi, is the most prevalent parasitic disease in the western hemisphere, infecting 8-11 million individuals and with over 70 million at risk. The infection is transmitted by an ins | Allergy and Infectious Diseases Research | September 5, 2023 | $2.9 million |
| Hybrid elisa: simple and specific one-tier assay for lyme disease - abstract lyme disease, caused by infection with the spirochete borrelia burgdorferi or closely related species, is the most common vector-borne disease in the united states, accounting for nearly 500,000 infections per year accordin | Allergy and Infectious Diseases Research | September 11, 2023 | $2.8 million |
| Serologic assays for detection of zika virus antibodies for clinical diagnosis and blood donor counseling | Allergy and Infectious Diseases Research | July 15, 2021 | $975,127 |
| Diagnostic assay for congenital chagas disease - project summary this project aims to develop a diagnostic test for congenital chagas disease (CCD), caused when infection with the protozoan trypanosoma cruzi is passed from mother to fetus during pregnancy. Chagas disease is the parasitic disease wit | Allergy and Infectious Diseases Research | April 26, 2024 | $606,500 |
| Development of an elisa for serosurveillance of human hookworm - hookworm infection, caused by necator americanus, ancylostoma duodenale, and ancylostoma ceylanicum is a leading cause of malnutrition and stunted growth in poor communities across sub-saharan africa, asia, and parts of south america. | Allergy and Infectious Diseases Research | March 27, 2023 | $600,000 |
| Peptide-based elisa for laboratory diagnosis of sarcoidosis - project summary sarcoidosis is a systemic inflammatory disease of unknown etiology characterized by granuloma formation in the lungs and other organs, affecting about 200,000 patients in the U.S. And over 1 million worldwide, with signifi | Trans-NIH Research Support | September 14, 2025 | $508,178 |
| Peptide-based elisa for laboratory diagnosis of sarcoidosis - project summary sarcoidosis is a systemic inflammatory disease of unknown etiology characterized by granuloma formation in the lungs and other organs, affecting about 200,000 patients in the U.S. And over 1 million worldwide, with signifi | Cardiovascular Diseases Research | September 14, 2025 | $470,013 |
| Micria: two-minute rapid assay platform for point-of-care diagnosis | Centers for Disease Control and Prevention Investigations and Technical Assistance | August 30, 2024 | $303,250 |
Questions people ask
How much federal grant money does Kephera Diagnostics LLC get?
$15.5 million in 11 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Kephera Diagnostics LLC the most?
The Department of Health and Human Services, with $15.5 million in 11 awards.
What is Kephera Diagnostics LLC's largest federal grant?
$3.0 million under Allergy and Infectious Diseases Research, with its first action in the period on March 30, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Kephera Diagnostics LLC?
Its largest are Allergy and Infectious Diseases Research, Trans-NIH Research Support and Cardiovascular Diseases Research.
Other grant recipients in Framingham
- Emergency Management Agency Massachusetts
- State Police Department
- Ameresco Inc
- Alzheon, Inc.
- Metrowest Regional Transit Authority
- Framingham State University
- South Middlesex Opportunity Council, Inc.
- Saga Innovations, Inc.
Largest federal grant recipients in Massachusetts · Federal grants in Massachusetts